Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Shire, a specialty biopharmaceutical company, has announced encouraging results from a 13-hour analog classroom study in school-aged children aged six to 12 years with attention deficit hyperactivity disorder.
Subscribe to our email newsletter
In this study, researchers found that Vyvanse controlled attention deficit hyperactivity disorder (ADHD) symptoms from the first time point measured (1.5 hours) through the last time point assessed (13 hours) post-dose. This study confirms the results of a previous clinical trial in which Vyvanse demonstrated ADHD symptom control throughout a 12-hour treatment day.
This randomized, double-blind, placebo-controlled, analog study assessed the efficacy and safety of Vyvanse in 129 children aged six to 12 years with ADHD. Following a four-week, open-label, dose-optimization phase with Vyvanse at 30mg, 50mg, and 70mg doses, patients entered a two-week, double-blind, crossover phase where they were randomized into two groups. One group received their optimal dose of Vyvanse the first week and placebo the second week. The second group received placebo the first week and their optimal dose of Vyvanse the second week.
The primary objective of this study was to assess the time of onset of Vyvanse compared with placebo, as measured by the Swanson, Kotkin, Agler, M-Flynn, and Pelham deportment (SKAMP-D) rating scale. Secondary objectives were to assess the duration of efficacy of Vyvanse compared with placebo, as measured by the SKAMP-D, SKAMP attention (SKAMP-A), and permanent product measure of performance (PERMP) scales.
In the study, Vyvanse demonstrated significant efficacy versus placebo at 1.5 hours, the first time point measured. Vyvanse treatment was associated with significant improvement in behavior and attention as measured by both subjective (SKAMP-D) and objective (PERMP) assessments from the first time point (1.5 hours) through the last time point (13 hours) assessed during the classroom day.
When measured using the PERMP scales, Vyvanse demonstrated significant improvement in math problems attempted and answered correctly with improvement for up to 13 hours post-dose. Safety was also evaluated during the study and Vyvanse was generally well tolerated.
Mike Cola, president of specialty pharmaceuticals business at Shire, said: “This is encouraging news for physicians and patients seeking a long-acting ADHD treatment option as this study demonstrated symptom control during a 13-hour treatment day. This Vyvanse study further supports Shire’s commitment to research efforts that address the need for ADHD symptom control throughout the day, and into the evening.”